Clinicopathological predictors of systemic progression and prostate cancer mortality in patients with a positive surgical margin at radical prostatectomy

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 1, 2012, Pages 56-62

  Boorjian, S A ^a   Tollefson, M K ^a   Rangel, L J ^a   Bergstralh, E J ^a   Karnes, R J ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

disease specific survival; PSA; radical prostatectomy; surgical margin

Indexed keywords

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

AGED; DISEASE PROGRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR BURDEN;

EID: 84857040602     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.36     Document Type: Article

References (38)

1. Chang SS, Cookson MS. Impact of positive surgical margins after radical prostatectomy. Urology 2006; 68: 249-252. (Pubitemid 44175518)
2. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001; 165: 119-125.
3. Stephenson AJ, Scardino PT, Eastham JA, Bianco Jr FJ, Dotan ZA, DiBlasio CJ et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23: 7005-7012.
4. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-578. (Pubitemid 41140332)
5. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D et al. Adjuvant radiotherapy for pathologically advanced prostate cancer. JAMA 2006; 296: 2329-2335. (Pubitemid 44749360)
6. Wieder JA, Soloway MS. Incidence, etiology, location, prevention, and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 1998; 160: 299-315. (Pubitemid 29476668)
7. Grossfeld GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC et al. Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. J Urol 2000; 163: 1171-1177. (Pubitemid 30169385)
8. Vis AN, Schröder FH, Van der Kwast TH. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol 2006; 50: 258-265. (Pubitemid 44038060)
9. Boorjian SA, Karnes RJ, Crispen PL, Carlson RE, Rangel LJ, Bergstralh EJ et al. The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol 2010; 183: 1003-1009.
10. Mann MJ, DeCastro GJ, Desai M, Benson MC, McKiernan JM. Predictive significance of surgical margin status after prostatectomy for prostate cancer during the PSA era. Urology 2008; 72: 1203-1207.
11. Epstein JI. Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin North Am 1996; 23: 651-663. (Pubitemid 27000030)
12. Simon MA, Kim S, Soloway MS. Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins. J Urol 2006; 175: 140-144. (Pubitemid 41797113)
13. Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2005; 174: 903-907. (Pubitemid 41140626)
14. Karakiewicz PI, Eastham JA, Graefen M, Cagiannos I, Stricker PD, Klein E et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 2005; 66: 1245-1250. (Pubitemid 41797299)
15. Eastham JA, Kuroiwa K, Ohori M, Serio AM, Gorbonos A, Maru N et al. Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology 2007; 70: 965-969. (Pubitemid 350192610)
16. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The longterm clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003; 170: 1872-1876. (Pubitemid 37254948)
17. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol 2004; 172: 910-914. (Pubitemid 39096421)
18. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439. (Pubitemid 41124175)
19. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011; 59: 893-899.
20. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-980. (Pubitemid 28445095)
21. Pfitzenmaier J, Pahernik S, Tremmel T, Haferkamp A, Buse S, Hohenfellner M. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression. BJU Int 2008; 102: 1413-1418.
22. Wright JL, Dalkin BL, True LD, Ellis WJ, Stanford JL, Lange PH et al. Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. J Urol 2010; 183: 2213-2218.
23. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Semin Surg Oncol 1994; 10: 60-72. (Pubitemid 24053289)
24. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165: 1146-1151. (Pubitemid 32210224)
25. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco Jr FJ, Lilja H et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006; 24: 3973-3978. (Pubitemid 46630746)
26. Jayachandran J, Bañez LL, Levy DE, Aronson WJ, Terris MK, Presti Jr JC et al. Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. J Urol 2008; 179: 1791-1796.
27. Resnick MJ, Canter DJ, Guzzo TJ, Magerfleisch L, Tomaszewski JE, Brucker BM et al. Defining pathological variables to predict biochemical failure in patients with positive surgical margins at radical prostatectomy: implications for adjuvant radiotherapy. BJU Int 2009; 105: 1377-1380.
28. Budäus L, Isbarn H, Eichelberg C, Lughezzani G, Sun M, Perrotte P et al. Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathologic stage. J Urol 2010; 184: 1341-1346.
29. Alkhateeb S, Alibhai S, Fleshner N, Finelli A, Jewett M, Zlotta A et al. Impact of positive surgical margins after radical prostatectomy differs by disease risk group. J Urol 2010; 183: 145-150.
30. Stephenson AJ, Wood DP, Kattan MW, Klein EA, Scardino PT, Eastham JA et al. Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol 2009; 182: 1357-1363.
31. Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007; 25: 4178-4186. (Pubitemid 47548556)
32. Dillman RO, Hafer R, Cox C, McClure SE. Overall survival benefit from postoperative radiation therapy for organ-confined, margin-positive prostate cancer. Int J Radiat Oncol Biol Phys 2011; 79: 719-723.
33. Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML. Radiation therapy after radical prostatectomy: impact on metastases and survival. J Urol 2009; 182: 2708-2714.
34. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760-2769. (Pubitemid 351846851)
35. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291: 1325-1332. (Pubitemid 38541647)
36. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy along in pT3 prostate cancer with postoperative undetectable prostate- specific antigen: ARO96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-2930.
37. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-962.
38. Mehta SS, Lubeck DP, Sadetsky N, Pasta DJ, Carroll PR. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol 2004; 171: 215-219. (Pubitemid 37549126)